OPKO Health, Inc. (OPK) Bundle
A Brief History of OPKO Health, Inc.
OPKO Health, Inc. has a complex history characterized by strategic acquisitions and developments in the healthcare sector. As of 2024, the company operates primarily in pharmaceuticals, diagnostics, and the transfer of intellectual property.
Financial Performance Overview
For the nine months ended September 30, 2024, OPKO reported total revenues of $529.5 million, a decrease of approximately 22% compared to $681.6 million for the same period in 2023. The revenue breakdown is as follows:
| Revenue Source | 2024 (in thousands) | 2023 (in thousands) | Change (in thousands) | % Change |
|---|---|---|---|---|
| Revenue from Services | $377,557 | $391,100 | $(13,543) | (3%) |
| Revenue from Products | $117,675 | $124,553 | $(6,878) | (6%) |
| Revenue from Transfer of Intellectual Property | $34,272 | $165,938 | $(131,666) | (79%) |
The decline in revenue from the transfer of intellectual property was notably impacted by a lack of one-time milestone payments that were recorded in the previous year. In 2023, OPKO received significant payments totaling $90 million from the FDA approval of NGENLA and $50 million from a Merck agreement.
Cost Structure and Profitability
OPKO's total costs and expenses for the nine months ended September 30, 2024, were $648.4 million, down from $769.6 million in the prior year, reflecting a decrease of 16%.
| Cost Type | 2024 (in thousands) | 2023 (in thousands) | Change (in thousands) | % Change |
|---|---|---|---|---|
| Cost of Revenue | $395,653 | $408,171 | $(12,518) | (3%) |
| Selling, General and Administrative | $237,191 | $227,676 | $9,515 | 4% |
| Research and Development | $74,789 | $70,199 | $4,590 | 7% |
| Amortization of Intangible Assets | $62,290 | $64,543 | $(2,253) | (3%) |
| Gain on Sale of Assets | $(121,493) | $0 | $(121,493) | (100%) |
The operating loss for the nine months ended was $118.9 million, compared to a loss of $88.0 million for the same period in 2023, reflecting a deterioration of 35% in operational efficiency.
Recent Developments
In September 2024, OPKO completed a significant transaction involving BioReference Laboratories, which included a gain of $121.5 million on the sale of assets. This transaction has been pivotal in shaping the company's financial landscape and future growth potential.
Cash Flow and Liquidity
As of September 30, 2024, OPKO reported cash, cash equivalents, and restricted cash totaling approximately $420.1 million. The cash used in operations for the nine months was $139.1 million, primarily driven by the aforementioned gain on asset sales and fluctuations in equity securities valuations.
Shareholder Equity
As of September 30, 2024, OPKO's total shareholders’ equity stood at $1.4 billion, with a significant accumulated deficit of $2.1 billion. This reflects ongoing challenges in achieving sustainable profitability.
| Equity Component | Amount (in thousands) |
|---|---|
| Common Stock | $7,124 |
| Treasury Stock | $(1,791) |
| Additional Paid-In Capital | $3,516,735 |
| Accumulated Other Comprehensive Loss | $(39,614) |
| Accumulated Deficit | $(2,079,037) |
| Total Shareholders’ Equity | $1,403,417 |
OPKO Health continues to adapt and respond to the challenges within the healthcare sector while aiming to leverage its assets and expertise for future growth.
A Who Owns OPKO Health, Inc. (OPK)
Major Shareholders
As of September 30, 2024, OPKO Health, Inc. has a diverse group of major shareholders, including both institutional investors and individual insiders. The following table summarizes the major shareholders and their respective ownership percentages:
| Shareholder | Ownership Percentage |
|---|---|
| Phillip Frost, M.D. (Chairman and CEO) | approximately 10.9% |
| Jane H. Hsiao, Ph.D. (Vice-Chairman) | approximately 5.3% |
| FMR LLC (Fidelity Investments) | approximately 8.2% |
| BlackRock, Inc. | approximately 6.4% |
| Vanguard Group, Inc. | approximately 5.6% |
| Other Institutional Investors | approximately 30.0% |
Insider Ownership
Insider ownership plays a significant role in the governance of OPKO Health. The following table provides details on the insider ownership as of September 30, 2024:
| Insider | Position | Shares Owned |
|---|---|---|
| Phillip Frost, M.D. | Chairman and CEO | approximately 85 million shares |
| Jane H. Hsiao, Ph.D. | Vice-Chairman | approximately 40 million shares |
| Adam Logal | CFO | approximately 5 million shares |
| Other Executives | Various | approximately 10 million shares |
Institutional Ownership
Institutional ownership is a critical aspect of OPKO Health's shareholder structure. The following table outlines the key institutional investors as of September 30, 2024:
| Institution | Shares Owned | Ownership Percentage |
|---|---|---|
| Fidelity Management & Research Company | approximately 63 million shares | 8.2% |
| BlackRock Fund Advisors | approximately 50 million shares | 6.4% |
| The Vanguard Group | approximately 43 million shares | 5.6% |
| State Street Global Advisors | approximately 35 million shares | 4.5% |
| Invesco Ltd. | approximately 30 million shares | 3.8% |
Recent Stock Performance
As of September 30, 2024, OPKO Health's stock price is approximately $2.10 per share, reflecting a market capitalization of approximately $1.6 billion. The stock has experienced a year-to-date performance of approximately 15% increase from the previous year, indicating a positive trend in investor sentiment.
Recent Developments
In January 2024, OPKO Health issued approximately $71.1 million in 2029 Convertible Notes, which has impacted the capital structure and liquidity position of the company. The company also announced a share repurchase program of up to $100 million, which may affect future ownership distributions among shareholders.
Conclusion on Ownership Structure
The ownership structure of OPKO Health, Inc. reflects a balanced mix of insider and institutional investors, with significant stakes held by the company's executives. The ongoing activities and strategic decisions made by these shareholders will continue to influence the company's operations and market performance.
OPKO Health, Inc. (OPK) Mission Statement
Company Overview
OPKO Health, Inc. is a diversified healthcare company that focuses on the development and commercialization of pharmaceuticals, diagnostics, and other healthcare solutions. As of 2024, the company has a mission to enhance patient outcomes and improve health through innovative technologies and solutions.
Mission Statement
OPKO Health, Inc. aims to be a leader in the healthcare industry by providing innovative solutions that improve patient care and enhance the quality of life. The company is committed to advancing healthcare through:
- Innovation: Developing cutting-edge technologies and products.
- Collaboration: Partnering with healthcare professionals and organizations to optimize patient outcomes.
- Integrity: Upholding the highest standards in all business practices.
- Access: Ensuring that patients have access to vital healthcare solutions.
Financial Performance
For the nine months ended September 30, 2024, OPKO Health reported the following financial metrics:
| Metric | 2024 (in thousands) | 2023 (in thousands) | Change (in thousands) | % Change |
|---|---|---|---|---|
| Total Revenues | $529,504 | $681,591 | $(152,087) | (22%) |
| Cost of Revenue | $395,653 | $408,171 | $(12,518) | (3%) |
| Selling, General and Administrative | $237,191 | $227,676 | $9,515 | 4% |
| Research and Development | $74,789 | $70,199 | $4,590 | 7% |
| Net Income (Loss) | $(67,251) | $(122,380) | $55,129 | 45% |
Revenue Breakdown
The revenue composition for the nine months ended September 30, 2024 is detailed below:
| Revenue Source | 2024 (in thousands) | 2023 (in thousands) | Change (in thousands) | % Change |
|---|---|---|---|---|
| Revenue from Services | $377,557 | $391,100 | $(13,543) | (3%) |
| Revenue from Products | $117,675 | $124,553 | $(6,878) | (6%) |
| Revenue from Transfer of Intellectual Property and Other | $34,272 | $165,938 | $(131,666) | (79%) |
Operational Highlights
During the third quarter of 2024, OPKO Health reported significant operational changes as part of its mission to streamline operations and improve financial performance:
- Cost Reduction Initiatives: The company implemented various measures leading to a decrease in selling, general, and administrative expenses.
- Strategic Partnerships: OPKO has entered into collaborations aimed at enhancing product offerings and expanding market reach.
- Focus on R&D: Despite a challenging environment, OPKO has increased its investment in research and development, reflecting a commitment to innovation.
Cash and Liquidity Position
As of September 30, 2024, OPKO Health reported the following liquidity metrics:
| Metric | Amount (in thousands) |
|---|---|
| Cash and Cash Equivalents | $420,100 |
| Total Long-Term Liabilities | $641,026 |
| Total Assets | $2,256,103 |
Conclusion
OPKO Health, Inc. continues to pursue its mission of improving patient care through innovative healthcare solutions while navigating the complexities of the healthcare market. The company's financial performance reflects the challenges and opportunities present in the industry as it strives to achieve its strategic goals.
How OPKO Health, Inc. (OPK) Works
Business Overview
OPKO Health, Inc. operates primarily in the healthcare sector, focusing on diagnostics and pharmaceuticals. The company is structured into two main segments: Diagnostics and Pharmaceuticals. OPKO provides a range of services and products, including laboratory testing, pharmaceuticals, and diagnostics solutions.
Financial Performance
As of September 30, 2024, OPKO Health reported the following financial results:
| Category | Three Months Ended September 30, 2024 | Three Months Ended September 30, 2023 | Nine Months Ended September 30, 2024 | Nine Months Ended September 30, 2023 |
|---|---|---|---|---|
| Total Revenues | $173,632,000 | $178,595,000 | $529,504,000 | $681,591,000 |
| Cost of Revenue | $159,416,000 | $243,002,000 | $648,430,000 | $769,566,000 |
| Operating Income (Loss) | $14,216,000 | ($64,407,000) | ($118,926,000) | ($87,975,000) |
| Net Income (Loss) | $24,890,000 | ($84,473,000) | ($67,251,000) | ($122,380,000) |
Revenue Breakdown
For the nine months ended September 30, 2024, revenue from services was broken down as follows:
| Payor Type | Amount (in thousands) |
|---|---|
| Healthcare Insurers | $229,600 |
| Government Payers | $63,561 |
| Client Payers | $71,521 |
| Patients | $12,875 |
Cost Structure
The costs associated with OPKO Health's operations for the nine months ended September 30, 2024 are as follows:
| Cost Category | Amount (in thousands) |
|---|---|
| Cost of Revenue | $648,430 |
| Selling, General and Administrative | $237,191 |
| Research and Development | $74,789 |
| Amortization of Intangible Assets | $62,290 |
Investment and Financing Activities
As of September 30, 2024, OPKO Health's cash, cash equivalents, and restricted cash stood at approximately $420.1 million. The company also reported cash flows from various activities:
| Category | Amount (in thousands) |
|---|---|
| Cash Used in Operations | ($139,100) |
| Cash from Investing Activities | $236,200 |
| Cash Provided by Financing Activities | $224,600 |
Debt and Interest Expenses
OPKO Health's interest expenses for the nine months ended September 30, 2024 were reported as follows:
| Category | Amount (in thousands) |
|---|---|
| Interest Income | $4,132 |
| Interest Expense | ($33,225) |
Research and Development Focus
Research and development expenses for the nine months ended September 30, 2024 included:
| Expense Type | Amount (in thousands) |
|---|---|
| Employee-Related Expenses | $28,132 |
| Other Internal R&D Expenses | $5,969 |
| Total R&D Expenses | $73,177 |
Tax Provisions
For the nine months ended September 30, 2024, OPKO Health reported an income tax provision of:
| Period | Tax Provision (in thousands) |
|---|---|
| Nine Months Ended September 30, 2024 | $21,900 |
| Nine Months Ended September 30, 2023 | $10,500 |
Market Position and Future Prospects
As of 2024, OPKO Health continues to focus on expanding its diagnostics services and pharmaceutical products, leveraging its strategic partnerships and ongoing research initiatives to enhance its market presence.
How OPKO Health, Inc. (OPK) Makes Money
Revenue Streams
OPKO Health, Inc. generates revenue through multiple streams, primarily from services, products, and the transfer of intellectual property. As of 2024, the breakdown of revenue is as follows:
| Revenue Source | 2024 (in thousands) | 2023 (in thousands) | Change (in thousands) | % Change |
|---|---|---|---|---|
| Revenue from Services | $377,557 | $391,100 | $(13,543) | (3.5%) |
| Revenue from Products | $117,675 | $124,553 | $(6,878) | (5.5%) |
| Revenue from Transfer of Intellectual Property | $34,272 | $165,938 | $(131,666) | (79.3%) |
| Total Revenues | $529,504 | $681,591 | $(152,087) | (22.3%) |
Revenue from Services
For the nine months ended September 30, 2024, OPKO's revenue from services decreased by approximately $13.5 million, primarily due to:
- A $6.5 million reduction in clinical test reimbursement rates.
- A $7.0 million decrease in clinical test volume, of which $3.3 million was attributed to the BioReference Transaction.
The composition of revenue from services by payer for the nine months ended September 30, 2024 is as follows:
| Payer Type | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Healthcare Insurers | $229,600 | $238,934 |
| Government Payers | $63,561 | $61,250 |
| Client Payers | $71,521 | $77,973 |
| Patients | $12,875 | $12,943 |
Revenue from Products
Revenue from products for the nine months ended September 30, 2024, decreased by $6.9 million or 5.5%. The primary product contributing to this revenue is Rayaldee, with sales generating $19.9 million compared to $21.7 million in the same period of 2023.
Revenue from Intellectual Property Transfers
Revenue from the transfer of intellectual property and other sources for the nine months ended September 30, 2024, was significantly lower at $34.3 million compared to $165.9 million in the prior year. This dramatic decrease was largely due to one-time milestone payments received in 2023, which included:
- $90.0 million payment triggered by the FDA approval of NGENLA (Somatrogon).
- $50.0 million payment from Merck for rights granted under the Merck Agreement.
- $7.0 million payment from VFMCRP triggered by the German price approval for Rayaldee.
- $2.5 million payment from Nicoya due to Nicoya’s submission of the investigational new drug application to China's Center for Drug Evaluation.
Cost of Revenue
For the nine months ended September 30, 2024, the total cost of revenue was $395.7 million, a decrease of $12.5 million or 3.1% compared to the same period in 2023. The breakdown is as follows:
| Cost Type | 2024 (in thousands) | 2023 (in thousands) | Change (in thousands) | % Change |
|---|---|---|---|---|
| Cost of Service Revenue | $325,798 | $333,460 | $(7,662) | (2.3%) |
| Cost of Product Revenue | $69,855 | $74,711 | $(4,856) | (6.5%) |
Selling, General and Administrative Expenses
Selling, general and administrative expenses for the nine months ended September 30, 2024, totaled $237.2 million, an increase of $9.5 million or 4.2% from the prior year. This increase was primarily driven by:
- Higher employee-related expenses.
- Professional fees related to international operations.
Research and Development Expenses
Research and development expenses for the nine months ended September 30, 2024, were $74.8 million, an increase of $4.6 million or 7.1% compared to 2023. The increase was attributed to:
- Growth in the BARDA collaboration.
- Higher employee-related expenses.
Income and Loss
For the nine months ended September 30, 2024, OPKO reported a net loss of $67.3 million compared to a net loss of $122.4 million for the same period in 2023. This improvement was largely due to the gain on sale of assets of $121.5 million from the BioReference Transaction in 2024.
Cash Position and Liquidity
As of September 30, 2024, OPKO had cash, cash equivalents, and restricted cash of approximately $420.1 million. Cash used in operations for the nine months ended September 30, 2024, was $139.1 million, primarily driven by the gain on the sale of assets and changes in fair value from equity securities.
Conclusion
In summary, OPKO Health, Inc. generates revenue through a diversified model including services, products, and intellectual property transfers. The company has seen fluctuations in revenue and expenses, impacting its overall financial health.
OPKO Health, Inc. (OPK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- OPKO Health, Inc. (OPK) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of OPKO Health, Inc. (OPK)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View OPKO Health, Inc. (OPK)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.